Autolus Therapeutics (AUTL)
(Delayed Data from NSDQ)
$2.47 USD
+0.14 (6.01%)
Updated Aug 11, 2025 04:00 PM ET
After-Market: $2.46 -0.01 (-0.40%) 5:34 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
AUTL 2.47 +0.14(6.01%)
Will AUTL be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AUTL based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for AUTL
Autolus Therapeutics Q2 2025 Earnings Preview
Autolus Therapeutics PLC (AUTL) Q2 2025 Earnings Report Preview: What To Look For
Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call ...
Analyst Reiterates Buy Rating on Autolus Therapeutics (AUTL) | AUTL Stock News